BCDA Share Price | BioCardia, Inc. Stock Analysis & Recommendation

Q: How big is BioCardia, Inc.?

Market Cap: As of Jun 18, BioCardia, Inc. has a market capitalization of 10.93 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, BioCardia, Inc. reported net sales of 0.00 million and a net profit of -8.40 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 0.84 million and total assets of 3.72 million.

Q: What does BioCardia, Inc. do?

Overview: BioCardia, Inc. is a clinical-stage regenerative medicine company engaged in developing therapeutics for cardiovascular diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025) Market cap: USD 10.93 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: 0.36 Return on Equity: 552.04% Price to Book: -7.19Contact Details: Address: 125 Shoreway Rd Ste B, SAN CARLOS CA: 94070-2718 Tel: 1 650 2260120 Website: http://www.biocardia.com/

Q: Is BioCardia, Inc. overvalued or undervalued?

As of 9 August 2023, BioCardia, Inc. has moved from a valuation grade of risky to does not qualify, indicating significant concerns regarding its financial health. The company is currently considered overvalued, especially given its negative financial ratios such as a Price to Book Value of -7.39 and an EV to EBITDA of -1.33. These figures suggest that the company's market valuation does not align with its underlying financial performance.In comparison to its peers, BioCardia's EV to EBIT ratio of -1.26 is slightly better than Frequency Therapeutics, Inc. at -1.3504, but worse than Landos Biopharma, Inc. at -2.9258. Additionally, the company's recent stock performance has been poor, with a year-to-date return of -7.34%, significantly lagging behind the S&P 500's 2.44% return. Overall, the combination of negative ratios and poor stock performance reinforces the conclusion that BioCardia, Inc. is overvalued in its current state.

Q: Is BioCardia, Inc. technically bullish or bearish?

As of 12 September 2025, the technical trend for BioCardia, Inc. has changed from sideways to mildly bearish. The weekly MACD is bearish, while the monthly MACD shows a mildly bullish stance, indicating mixed signals across time frames. The Bollinger Bands and Dow Theory both reflect a bearish outlook on a weekly and monthly basis. Daily moving averages are also bearish, further supporting the negative sentiment. The KST is bearish weekly but mildly bullish monthly, adding to the complexity of the analysis. Overall, the indicators suggest a mildly bearish stance, with the stock underperforming compared to the S&P 500, although specific return data is not available for comparison.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

220.94 k

Shareholding (Sep 2025)

FII

0.01%

Held by 3 FIIs

DII

98.67%

Held by 1 DIIs

Promoter

0.00%

How big is BioCardia, Inc.?

22-Jun-2025

As of Jun 18, BioCardia, Inc. has a market capitalization of 10.93 million, with net sales of 0.00 million and a net profit of -8.40 million over the last four quarters. The company reported shareholder's funds of 0.84 million and total assets of 3.72 million as of Dec 24.

View full answer

What does BioCardia, Inc. do?

22-Jun-2025

BioCardia, Inc. is a clinical-stage regenerative medicine company focused on developing therapeutics for cardiovascular diseases, with a market cap of $10.93 million and a recent net profit of -$3 million. The company operates in the Pharmaceuticals & Biotechnology industry and has a debt equity ratio of 0.36.

View full answer

Who are in the management team of BioCardia, Inc.?

22-Jun-2025

As of March 2022, the management team of BioCardia, Inc. includes Dr. Simon Stertzer (Independent Chairman), Dr. Peter Altman (CEO), Dr. Krisztina Zsebo, and several independent directors: Jim Allen, Andrew Blank, Fernando Fernandez, and Richard Krasno. They oversee the company's strategic direction and operations.

View full answer

Is BioCardia, Inc. overvalued or undervalued?

25-Jun-2025

As of August 9, 2023, BioCardia, Inc. is considered overvalued and has moved to a "does not qualify" valuation grade due to negative financial ratios and poor stock performance, with a year-to-date return of -7.34% compared to the S&P 500's 2.44%.

View full answer

Is BioCardia, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, BioCardia, Inc. shows a mildly bearish trend with mixed technical indicators, including bearish weekly MACD and moving averages, despite a mildly bullish monthly MACD.

View full answer

Compare BioCardia, Inc. with Similar Stocks

Athersys, Inc.Aravive, Inc.Imunon, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 7 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.85

Return on Equity

-325.09%

Price to Book

2.83

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-6.77%

6 Months

-36.73%

1 Year

-51.75%

2 Years

-80.64%

3 Years

-47.9%

4 Years

-95.8%

5 Years

-98.33%

BioCardia, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-11.92%

EBIT Growth (5y)

7.08%

EBIT to Interest (avg)

-11.56

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.36

Sales to Capital Employed (avg)

-0.15

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

4.34%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-7.39

EV to EBIT

-1.26

EV to EBITDA

-1.33

EV to Capital Employed

-5.16

EV to Sales

10.69

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Sideways

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 3 Schemes (1.33%)

Foreign Institutions

Held by 3 Foreign Institutions (0.01%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 25.93% vs -17.39% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.90",
          "val2": "-2.60",
          "chgp": "26.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.00",
          "val2": "-2.70",
          "chgp": "25.93%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -80.00% vs -64.29% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 31.90% vs 2.52% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.50",
          "chgp": "-80.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.60",
          "val2": "-11.20",
          "chgp": "32.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.90",
          "val2": "-11.60",
          "chgp": "31.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-137,948.30%",
          "val2": "-24,410.90%",
          "chgp": "-11,353.74%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-1.90

-2.60

26.92%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-2.00

-2.70

25.93%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 25.93% vs -17.39% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.10

0.50

-80.00%

Operating Profit (PBDIT) excl Other Income

-7.60

-11.20

32.14%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-7.90

-11.60

31.90%

Operating Profit Margin (Excl OI)

-137,948.30%

-24,410.90%

-11,353.74%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -80.00% vs -64.29% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 31.90% vs 2.52% in Dec 2023

All Annual Results

Company CV

About BioCardia, Inc.

BioCardia, Inc.

Pharmaceuticals & Biotechnology

BioCardia, Inc. is a clinical-stage regenerative medicine company engaged in developing therapeutics for cardiovascular diseases. The Company's therapeutic portfolio consists of the CardiAMP and CardiALLO cell therapies. The Company's lead therapeutic candidate is the CardiAMP Cell Therapy System (CardiAMP) and focuses on the Phase III trial for CardiAMP in ischemic systolic heart failure. The Company's CardiALLO Cell Therapy System (CardiALLO), is an allogeneic off the shelf mesenchymal stem cell product candidate from other donors. The Company’s products also include Helix Biotherapeutic Delivery System and Morph Deflectable Guide and Sheaths Products.

Company Coordinates

Company Details

125 Shoreway Rd Ste B , SAN CARLOS CA : 94070-2718

Tel: 1 650 2260120

http://www.biocardia.com/

Registrar Details

BioCardia, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is BioCardia, Inc.?

Watch in Real-Time

What does BioCardia, Inc. do?

Who are in the management team of BioCardia, Inc.?

Is BioCardia, Inc. overvalued or undervalued?

Is BioCardia, Inc. technically bullish or bearish?

Compare BioCardia, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About BioCardia, Inc.

Company Coordinates